Alumis eyes late-stage lupus study despite trial miss

Alumis said it will advance its experimental drug in a smaller subset of patients after the mid-stage trial failed to meet its primary endpoint. The update suggests continued development potential but acknowledges a key efficacy miss, keeping near-term risk elevated for the program.